Loxoprofen
A prodrug NSAID that is converted to its active form in the body, used in Japan and other Asian countries to treat pain and inflammation from arthritis and musculoskeletal conditions. It may have a lower rate of gastrointestinal side effects than some other NSAIDs.
Molekularmasse
246,3000 g/mol
LogP
2,40
TPSA
54,40 Ų
Lipinski-Regel der Fünf
Bestanden
Therapeutische Bereiche
Wirkmechanismus
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
2D-Struktur
Cite this structure
Embed this structure
SMILES
CC(C(=O)O)c1ccc(CC2CCCC2=O)cc1
InChI
InChI=1S/C15H18O3/c1-10(15(17)18)12-7-5-11(6-8-12)9-13-3-2-4-14(13)16/h5-8,10,13H,2-4,9H2,1H3,(H,17,18)
Molecular Formula
C15H18O3
HBD / HBA
1 / 3
Rotierbare Bindungen
4
Schwere Atome
18
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
A prodrug NSAID that is converted to its active form in the body, used in Japan and other Asian countries to treat pain and inflammation from arthritis and musculoskeletal conditions. It may have a lower rate of gastrointestinal side effects than some other NSAIDs.
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Yes, Loxoprofen is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL19299. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 3965. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="loxoprofen"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/loxoprofen/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/loxoprofen/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/loxoprofen/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="loxoprofen"></drugfyi-drug>